Physician profile
Meredith Evans
NPI 1700347200
$6,551.69
in general payments reported to CMS, 2019-2025
39 companies · $664 in 2025
The $664 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,890 · 2022: $588 · 2023: $800 · 2024: $609 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,372.75 | 2021 | |
| Abbvie INC. | $722.58 | 2021-2025 | |
| Novo Nordisk INC | $386.96 | 2021-2023 | Ozempic, Rybelsus |
| Amgen INC. | $364.40 | 2021-2023 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $348.06 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $344.02 | 2021-2025 | |
| Esperion Therapeutics, INC. | $321.43 | 2021 | |
| Astellas Pharma US INC | $285.67 | 2021-2025 | Veozah |
| Abbott Laboratories | $253.51 | 2023-2025 | Freestyle Libre 3, Id Now Instrument |
| Astrazeneca Pharmaceuticals LP | $235.97 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $196.75 | 2021-2025 | |
| Glaxosmithkline, LLC. | $175.54 | 2021-2025 | Shingrix, Bexsero, Pediarix |
| Dexcom, INC. | $173.13 | 2022-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $166.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.61 | 2021-2025 | Jardiance, Synjardy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.